Ionis announces license agreement with Recordati for zilganersen in Alexander disease (AxD) in all countries outside the U.S.
Ionis granted Recordati exclusive rights to develop and commercialize zilganersen for Alexander disease outside the U.S., receiving $30 million upfront plus potential milestones and tiered royalties. Ionis retains sole commercial rights in the U.S., where the drug is under FDA review with a PDUFA target date of September 22, 2026.
Key figures
- Drug Name
- zilganersen
- Deal Value Usd
- 30000000
- Pdufa Date
- September 22, 2026
- Royalties
- mid-20% range
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.